Physician profile
Robert Chong
NPI 1467428524
$1,144.94
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $726 · 2020: $268 · 2021: $151.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medimetriks Pharmaceuticals, INC. | $437.87 | 2019 | |
| Cook Medical LLC | $214.16 | 2020-2021 | |
| Bioventus LLC | $140.96 | 2019 | |
| Smith+Nephew, INC. | $87.21 | 2019-2020 | |
| Cardiovascular Systems INC. | $75.88 | 2020 | |
| Zyla Life Sciences, INC. | $61.68 | 2019 | |
| Sandoz INC. | $36.32 | 2020 | |
| Paragon 28, INC. | $24.30 | 2019 | |
| Zimmer Biomet Holdings, INC. | $20.12 | 2020 | |
| Melinta Therapeutics, LLC | $17.64 | 2020 | |
| Merck Sharp & Dohme LLC | $16.10 | 2019 | |
| Nabriva Therapeutics, Plc | $12.70 | 2020 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.